| Literature DB >> 26170167 |
Jiang Chen1, Renan Jin1, Jie Zhao1, Jinghua Liu1, Hanning Ying1, Han Yan1, Senjun Zhou1, Yuelong Liang1, Diyu Huang1, Xiao Liang1, Hong Yu1, Hui Lin2, Xiujun Cai3.
Abstract
Sorafenib, an orally-available kinase inhibitor, is the only standard clinical treatment against advanced hepatocellular carcinoma. However, development of resistance to sorafenib has raised concern in recent years due to the high-level heterogeneity of individual response to sorafenib treatment. The resistance mechanism underlying the impaired sensitivity to sorafenib is still elusive though some researchers have made great efforts. Here, we provide a systemic insight into the potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma depending on abundant previous studies and reports.Entities:
Keywords: Acquired resistance; Advanced hepatocellular carcinoma (HCC); Cancer stem cells (CSCs); Epithelial–mesenchymal transitions (EMT) and mesenchymal–epithelial transitions (MET); Microenvironment
Mesh：
Substances：
Year: 2015 PMID： 26170167 DOI： 10.1016/j.canlet.2015.06.019
Source DB: PubMed Journal: Cancer Lett ISSN： 0304-3835 Impact factor: 8.679